eLife · 2018
Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin resistance.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fazakerley Daniel J, Chaudhuri Rima, Yang Pengyi, Maghzal Ghassan J, Thomas Kristen C, Krycer James R, Humphrey Sean J, Parker Benjamin L, Fisher-Wellman Kelsey H, Meoli Christopher C, Hoffman Nolan J, Diskin Ciana, Burchfield James G, Cowley Mark J, Kaplan Warren, Modrusan Zora, Kolumam Ganesh, Yang Jean Yh, Chen Daniel L, Samocha-Bonet Dorit, Greenfield Jerry R, Hoehn Kyle L, Stocker Roland, James David E
Аннотация
OBJECTIVE: The purpose of this study was to explore the effect of a new cardiac rehabilitation mode on the cardiac function, mental state and quality of life of patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI) with atorvastatin calcium tablets.
PATIENTS AND METHODS: A total of 120 AMI patients treated with PCI and atorvastatin calcium tablets between January 2018 and January 2019 were recruited and assigned 1:1 to receive either novel cardiac rehabilitation (experimental group) or conventional cardiac rehabilitation (control group), with 60 cases in each group. Outcome measures for evaluating the effectiveness of the novel cardiac rehabilitation mode included cardiac function indices, 6 minutes walking distance test (6MWD), adverse mental state, quality of life (QOL), incidence of complications, and satisfaction on recovery.
RESULTS: Patients after novel cardiac rehabilitation care showed better cardiac function than those with conventional care (p<0.001). Patients had longer 6MWD and higher QOL after novel cardiac rehabilitation care vs. those given conventional care (p<0.001). The lower scores of adverse mental state in the experimental group suggested a better psychological status of patients after receiving novel cardiac rehabilitation care when compared with those with conventional care (p<0.001). Patients were also more satisfied with the novel modality of cardiac rehabilitation care than with conventional care (p<0.05).
CONCLUSIONS: The new cardiac rehabilitation mode can effectively improve the cardiac function of AMI patients after PCI plus atorvastatin calcium tablets, enhance their cardiac function, mitigate their negative emotions, and reduce the risk of complications. Further trials are required prior to clinical promotion.
PATIENTS AND METHODS: A total of 120 AMI patients treated with PCI and atorvastatin calcium tablets between January 2018 and January 2019 were recruited and assigned 1:1 to receive either novel cardiac rehabilitation (experimental group) or conventional cardiac rehabilitation (control group), with 60 cases in each group. Outcome measures for evaluating the effectiveness of the novel cardiac rehabilitation mode included cardiac function indices, 6 minutes walking distance test (6MWD), adverse mental state, quality of life (QOL), incidence of complications, and satisfaction on recovery.
RESULTS: Patients after novel cardiac rehabilitation care showed better cardiac function than those with conventional care (p<0.001). Patients had longer 6MWD and higher QOL after novel cardiac rehabilitation care vs. those given conventional care (p<0.001). The lower scores of adverse mental state in the experimental group suggested a better psychological status of patients after receiving novel cardiac rehabilitation care when compared with those with conventional care (p<0.001). Patients were also more satisfied with the novel modality of cardiac rehabilitation care than with conventional care (p<0.05).
CONCLUSIONS: The new cardiac rehabilitation mode can effectively improve the cardiac function of AMI patients after PCI plus atorvastatin calcium tablets, enhance their cardiac function, mitigate their negative emotions, and reduce the risk of complications. Further trials are required prior to clinical promotion.